Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Tax Provisions: 2021-2025

Historic Tax Provisions for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Sep 2025 value amounting to $111,000.

  • Rhythm Pharmaceuticals' Tax Provisions rose 132.27% to $111,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $438,000, marking a year-over-year decrease of 32.82%. This contributed to the annual value of $346,000 for FY2024, which is 38.65% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Tax Provisions stood at $111,000 for Q3 2025, which was down 67.06% from $337,000 recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Tax Provisions high stood at $22.0 million for Q1 2021, and its period low was -$9.0 million during Q3 2021.
  • Moreover, its 3-year median value for Tax Provisions was $196,000 (2023), whereas its average is $162,000.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Tax Provisions tumbled by 193.48% in 2024, and later spiked by 132.27% in 2025.
  • Quarterly analysis of 4 years shows Rhythm Pharmaceuticals' Tax Provisions stood at -$9.0 million in 2021, then reached $196,000 in 2023, then slumped by 145.92% to -$90,000 in 2024, then surged by 132.27% to $111,000 in 2025.
  • Its last three reported values are $111,000 in Q3 2025, $337,000 for Q2 2025, and $80,000 during Q1 2025.